|Last Price||Today's Change||52-Week Range||Trading Volume|
|57.56||0.63 (+1.11%)||52.49 - 63.62||6.5 million (Below Avg)|
Market data as of 3:26PM 07/01/15. Quotes are delayed by at least 15 min.
Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
06/29/2015 8:30 AM ET
Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28
06/26/2015 8:00 AM ET